"Cancer is the first leading cause of death in Taiwan. Targeted therapy allows cancer cells to be specifically targeted, reduces the side effects,achieves the purpose of precision cancer treatment. 
 
 This report contains two inventions of technology. The first invention is the early & specific diagnosis of a specific Aurora-A mRNA isoform in cancers (the companion diagnosis). The second invention is inhibiting the translation of this Aurora-A mRNA isoform (targeted therapy) in cancers by treating with a selective locked nucleic acid (LNA)-modified novel double-stranded short interfering nucleic acid (siRNA)."

"In the past 20 years, small molecule inhibitors have been used to inhibit the overexpressed Aurora-A in cancers. However, those inhibitors lack specificitymay cause serious side effects. 
 
 The specificnovel double-stranded short interfering nucleic acid (siRNA) was designed according to the computer simulated RNA structure of the specific Aurora-A mRNA 5’-UTR isoform.
 
 The probe used for companion diagnosis was synthesized using an overlapping coverage strategy to increase the specificitysensitivity for detecting the expression of the specific Aurora-A mRNA 5’-UTR isoform."

"This invention is an LNA-modified siRNA which can selectively inhibit the translation of a specific Aurora-A mRNA isoform (targeted therapy) in cancers. It is a patent protected siRNA with excellent anti-cancer ability it has the potential to become an anti-cancer drugapply to cancer therapy. 
 
 The probe chip is able to detect the tumor-specific Aurora-A mRNA isoform. Its function is the companion diagnosis for Aurora-A mRNA isoform selective siRNA drug treatment. In addition, this chip can also be used for the early detection of precancerous lesions."